Cello Health GmbH has opened in Berlin with its Business Insights and Analytics division, Cello Health Insight, appointing two regional directors: Heike Tombrink – Regional Director, Head of Cello Health Insight Germany, and Matthias Heurich – Regional Director, supporting Digital Innovation.
Heike Tombrink brings to Cello Health Insight more than 20 years of expertise as a strategic market research consultant, having worked internationally for Pharma (RX, OTC, Vaccines), Medical Supplies and MedTech companies as well as associated industries and academia. She is versed in applying the entire spectrum of classical and new research methods to provide practical guidance to clients’ business decisions, pre- and post- launch.
Tombrink has been leading small and large teams in and outside of matrix organizations and will function as the country head of Cello Health Insight in Germany.
Matthias Heurich also brings a wealth of Pharma market research expertise, having previously worked client-side as a market research consultant at Eli Lilly. His main focus is on large-scale quantitative studies and advanced analytics, which integrates with his experience in digital innovation gained in the technology sector. Heurich’s specialism is in applied machine learning and artificial intelligence for natural language processing, which focuses on utilising new technologies to innovate understanding of consumers on the basis of already existing data. This expertise will form a key part of his new role supporting Digital Innovation at Cello Health Insight.
Jane Shirley, CEO Cello Health Europe, said: “Opening in mainland Europe will bring with it a number of benefits, and is a key part of our overall strategy. This is an important first step in providing additional on the ground support for our current European clients, and also accessing a wider talent pool as we grow.”
Kudos Research, Cello Health’s premium quality, data collection and analysis unit, already has a new telephone unit in place in Berlin led by Divisional Director Volker Balk, which opened in March this year.
Cello Health and BresMed join forces to support value demonstration and optimise patient access for new biopharma therapies
Join us at the Pharmaceutical Management Science Association Virtual Meeting December 3-4, 2020 and visit our poster on Analogue Intelligence: Growing Both Players in a Duopoly Market, a case study from our growing practice in identifying and extracting learnings from analogues facing similar strategic challenges.
The acquisition of Cello Health provides the foundation for a new enterprise to enable healthcare and biopharmaceutical clients to maximize the value of their products.
The journey to scientific and commercial success is often complex and always critical, if you are looking for an expert partner to help steer you to confident solutions, contact us todayContact us